OXB.L - Oxford BioMedica PLC

LSE - LSE Delayed price. Currency in GBp
14.975
-0.025 (-0.17%)
As of 10:36AM BST. Market open.
Stock chart is not supported by your current browser
Previous close15.000
Open15.020
Bid14.940 x 2513500
Ask14.980 x 11600000
Day's range14.894 - 15.020
52-week range4.880 - 15.500
Volume1,349,457
Avg. volume7,150,511
Market cap491.825M
Beta-0.73
PE ratio (TTM)N/A
EPS (TTM)-0.300
Earnings date15 Aug 2018 - 20 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est17.55
  • Reuters3 months ago

    Oxford BioMedica wins second $100 million gene therapy contract

    Britain's Oxford BioMedica has won a second $100 million (£71.2 million) contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion. Oxford Bio said on Thursday it would receive $5 million upfront and would be eligible for various milestone payments, potentially worth in excess of $100 million, plus royalties on sales of haemophilia therapies that Bioverativ is developing. The deal follows a similar $100 million contract last year to supply lentiviral vectors, which are used to deliver DNA into cells, for Novartis's pioneering leukaemia treatment Kymriah.

  • Reuters - UK Focus3 months ago

    Oxford BioMedica wins second $100 mln gene therapy contract

    Britain's Oxford BioMedica (LSE: OXB.L - news) has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi (LSE: 0O59.L - news) for $11.6 billion. Oxford Bio said on Thursday it would receive $5 million upfront and would be eligible for various milestone payments, potentially worth in excess of $100 million, plus royalties on sales of haemophilia therapies that Bioverativ is developing. The deal follows a similar $100 million contract last year to supply lentiviral vectors, which are used to deliver DNA (Frankfurt: 24D.F - news) into cells, for Novartis (IOB: 0QLR.IL - news) 's pioneering leukaemia treatment Kymriah.

  • Reuters - UK Focus9 months ago

    BUZZ-Oxford BioMedica: shares jump 12 pct as U.S. approves gene therapy

    ** Oxford BioMedica shares up 12% as Novartis wins approval for pioneering leukaemia treatment, marking the first gene therapy approval in the United States ** UK company makes virus-based gene delivery ...

  • Reuters - UK Focus9 months ago

    Profit finally in sight for gene therapy specialist Oxford Bio

    After 20 years of losses, gene therapy specialist Oxford BioMedica (LSE: OXB.L - news) is at last close to achieving its first profit thanks to the success of Novartis with a pioneering cancer treatment. As manufacturer of the virus-based gene delivery system central to the Novartis therapy, which re-engineers a patient's immune cells to attack cancer, the small British company will receive a modest slice of the revenue once the new drug is approved.

  • Reuters - UK Focus11 months ago

    Oxford BioMedica wins big contract for Novartis cell therapy

    Novartis (IOB: 0QLR.IL - news) has signed a major contract with Oxford BioMedica (LSE: OXB.L - news) that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019. The deal, announced by Oxford BioMedica on Thursday, could help put the veteran biotech firm on a path to sustainable profitability. The contract is for the supply of lentiviral vectors used to generate CTL019, a new kind of treatment for hard-to-treat leukaemia that is expected to reach the market this year.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes